0001104659-22-001252.txt : 20220105 0001104659-22-001252.hdr.sgml : 20220105 20220105071421 ACCESSION NUMBER: 0001104659-22-001252 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220103 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220105 DATE AS OF CHANGE: 20220105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BICYCLE THERAPEUTICS plc CENTRAL INDEX KEY: 0001761612 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38916 FILM NUMBER: 22509429 BUSINESS ADDRESS: STREET 1: B900 BABRAHAM RESEARCH CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB22 3AT BUSINESS PHONE: 011441223261503 MAIL ADDRESS: STREET 1: B900 BABRAHAM RESEARCH CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB22 3AT FORMER COMPANY: FORMER CONFORMED NAME: BICYCLE THERAPEUTICS Ltd DATE OF NAME CHANGE: 20181212 8-K 1 tm221573d1_8k.htm FORM 8-K
0001761612 false 00-0000000 true 0001761612 2022-01-03 2022-01-03 0001761612 us-gaap:CommonStockMember 2022-01-03 2022-01-03 0001761612 bcyc:AmericanDepositarySharesMember 2022-01-03 2022-01-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

January 3, 2022

Date of Report (Date of earliest event reported)

 

Bicycle Therapeutics plc

(Exact name of registrant as specified in its charter)

 

England and Wales   001-38916   Not applicable

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

B900, Babraham Research Campus

Cambridge CB22 3AT

United Kingdom

 Not Applicable
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: +44 1223 261503

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Ordinary shares, nominal value £0.01 per share n/a The Nasdaq Stock Market LLC*
American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share BCYC The Nasdaq Stock Market LLC

* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). 

Emerging growth company    ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

  

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On January 5, 2022, Bicycle Therapeutics plc (the “Company”) announced the appointment of Alistair Milnes, age 48, as the Company’s Chief Operating Officer, effective as of January 3, 2022 (the “Effective Date”). Mr. Milnes assumes the role of Chief Operating Officer following the transition of Michael Skynner, Ph.D. to the newly-created role of Chief Technology Officer of the Company as of the Effective Date.

 

Mr. Milnes joined the Company in January 2021 as Vice President, Human Resources and Communications. Prior to joining the Company, Mr. Milnes provided independent human resources consulting services, including to the Company, from October 2020 to December 2020. He also previously served as Strategic Advisor, Transformation, People and Communications at Rio Tinto from January 2020 to December 2020, and in roles of increasing responsibility at Gazprom Marketing & Trading Ltd. from 2010 to October 2019, including serving as Director of Global Human Resources from December 2013 to November 2017, following which he became Director of Global Human Resources and Communications. Mr. Milnes received his B.A. from Edinburgh Napier University.

 

Mr. Milnes’ service as Chief Operating Officer of the Company is governed by a service agreement, effective as of the Effective Date, between BicycleTx Ltd. (“BicycleTx”) and Mr. Milnes (the “Service Agreement”). Pursuant to the terms of the Service Agreement, Mr. Milnes will receive an annual base salary of £365,000 and is eligible to earn an annual cash incentive award based on performance with a target value equal to 50% of his annual base salary. Mr. Milnes remains eligible to participate in BicycleTx’s employee benefit plans generally available to BicycleTx executive employees, subject to the terms of those plans.

 

In connection with his appointment and pursuant to the Service Agreement, the Compensation Committee of the Board of Directors of the Company (the “Compensation Committee”) approved a grant to Mr. Milnes on the Effective Date of an option (the “Option”) to purchase 70,000 of the Company’s ordinary shares, nominal value £0.01 per share (the “Ordinary Shares”), pursuant to the Company’s 2020 Equity Incentive Plan. Twenty-five percent of the Ordinary Shares underlying the Option will vest on the first anniversary of the Effective Date, and the remainder of the Ordinary Shares underlying the Option will vest in 36 equal installments monthly thereafter, subject to Mr. Milnes’ continued employment through each such vesting date. Mr. Milnes also received an annual equity incentive award grant commensurate with those received by the Company’s other executive officers on the Effective Date, pursuant to the Company’s standard equity compensation arrangements approved by the Compensation Committee.

 

Mr. Milnes’ employment has no specified term but can be terminated by either party in writing giving the other no less than six months’ notice. Mr. Milnes’ employment may be terminated, immediately and without notice, pursuant to the conditions specified in the Service Agreement, in which event Mr. Milnes would then be entitled to certain accrued obligations and may, depending on the circumstances, be entitled to receive payment in lieu of salary and benefits for all or any part of the notice period to which he would otherwise have been entitled. If Mr. Milnes’ employment is terminated as a result of his death, by BicycleTx without Cause (as defined in the Service Agreement) or by Mr. Milnes for Good Reason (as defined in the Service Agreement), BicycleTx will owe Mr. Milnes severance pay, the amount of which will depend on whether such termination occurs within the 12-month period following a Change of Control (as defined in the Service Agreement) of the Company. If such termination occurs within such 12-month period, Mr. Milnes would be entitled to receive a payment equal to 12 months of his then-annual salary, his target annual performance bonus for the year of termination, and benefits continuation (or cash in lieu thereof) for 12 months following his termination. Any equity awards held by Mr. Milnes subject to time-based vesting would also become fully vested. If such termination occurs other than within the 12-month period following a Change of Control (as defined in the Service Agreement) of the Company, Mr. Milnes would be entitled to receive a payment equal to nine months of his then annual salary, and benefits continuation (or cash in lieu thereof) for nine months following termination. The Service Agreement also binds Mr. Milnes to customary confidentiality, intellectual property and post-termination covenants.

 

 

 

 

 In connection with his appointment as Chief Operating Officer, Mr. Milnes will also execute the Company’s standard form of deed of indemnity, the form of which was filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (“SEC”) on November 12, 2019.

 

Mr. Milnes was not selected as an officer of the Company pursuant to any understanding or arrangement between him and any other person, he has no family relationships with any of the Company’s directors or executive officers, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

 

The foregoing description of the Service Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Service Agreement, which will be filed as an exhibit to a subsequent filing with the SEC.

 

Item 7.01 Regulation FD Disclosure.

 

On January 5, 2022, the Company posted an updated corporate presentation on the Company’s website. To access the presentation, investors should visit the “Investor Events and Presentations” section of the Company’s website at investors.bicycletherapeutics.com.

 

The information furnished under this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the SEC made by the Company, regardless of any general incorporation language in such filing.

 

Item 8.01 Other Events.

 

On January 5, 2022, the Company issued a press release announcing continued clinical progress in its ongoing Phase I/II clinical trials of BT8009, BT5528, and BT7480, as well as the management transitions described in Item 5.02 of this Current Report on Form 8-K. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 8.01 by reference.

 

Item 9.01 Financial Statements and Exhibits

 

(a)       Exhibits

 

99.1 Press Release issued January 5, 2022
104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 

  

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: January 5, 2022 BICYCLE THERAPEUTICS PLC
   
  By: /s/ Lee Kalowski
  Name: Lee Kalowski
  Title: Chief Financial Officer

 

 

 

 EX-99.1 2 tm221573d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

  

Bicycle Therapeutics Announces Continued Clinical Progress and Updates to Management Team

  

CAMBRIDGE, England, & BOSTON, January 5, 2022 – Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced continued progress in its ongoing Phase I/II clinical trials of BT8009, BT5528 and BT7480.

 

“Last quarter, we reported interim clinical results from ongoing trials of two of our Bicycle toxin conjugates, BT8009 and BT5528, demonstrating preliminary anti-tumor activity in two tumor types, and announced the first patient dosed in the Phase I clinical trial of BT7480, our first tumor-targeted immune cell agonist to enter the clinic. In our trial of BT8009, we are pleased to confirm the preliminary activity and see that these patients remain on trial. We look forward to presenting interim BT8009 Phase I results at a medical meeting and initiating the BT5528 expansion cohorts this year,” said Kevin Lee, Ph.D., Chief Executive Officer. “We are also pleased with our progress advancing BT7480 in the ongoing Phase I clinical trial and look forward to sharing additional details regarding the potential for Bicycles beyond our toxin conjugates as we strive to become a leader in the development of targeted oncology therapeutics.”

 

Bicycle Toxin Conjugates® (BTCs) BT8009 and BT5528

 

In the ongoing Phase I portion of the Phase I/II clinical trial of BT8009, a second-generation BTCTM targeting Nectin-4, four out of 11 patients were previously reported to have a partial response under Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, including one out of four (25%) in the 2.5mg/m2 dose and three out of seven (43%) at the 5.0 mg/m2 cohorts. All four patients previously reported as responders have since received at least one subsequent scan, and all have been confirmed as ongoing RECIST 1.1 responses. One patient in the 5.0 mg/m2 cohort, who previously was reported to have a partial response with an 89% tumor reduction, has now received two subsequent scans, which each showed that total tumor volume has been reduced by 100%, constituting a confirmed complete response. All four patients previously reported to have a RECIST 1.1 clinical response remain on therapy. The tolerability profile of the 2.5mg/m2 and 5.0 mg/m2 cohorts remains consistent with that previously reported.

 

Dose escalation in the BT8009 Phase I trial remains ongoing, with patients currently being dosed at 7.5mg/m2 weekly or every-other-week. Bicycle intends to present interim Phase I results from the ongoing clinical trial at a medical meeting this year.

 

The Phase I/II trial of BT5528, Bicycle’s second-generation BTC targeting EphA2, is also ongoing, with plans remaining on track to initiate the expansion cohorts this year, with an expected recommended Phase II dose of 6.5mg/m2 every-other-week.

 

Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™) BT7480

 

Bicycle also initiated a Phase I clinical trial of BT7480, a novel, fully synthetic Bicycle TICA targeting Nectin-4 and agonizing CD137, in the fourth quarter of 2021, and dose escalation in that trial remains ongoing. BT7480 and other Bicycle TICAs, including a novel NK-cell-engaging molecule, were the subjects of four posters at SITC in November 2021.

 

 

 

 

 

Management Team Updates

 

Bicycle is also announcing the expansion of and transition in its management team. Michael Skynner, Ph.D., the company’s Chief Operating Officer (COO), has been appointed to the newly created position of Chief Technology Officer, effective January 3, 2022, to focus on leading and overseeing the growth of Bicycle’s proprietary phage display discovery platform in oncology, as well as on creating innovative opportunities for the platform outside of oncology. Dr. Skynner joined the company in January 2016 as Vice President, Operations and Discovery and had served as COO since March 2018. Alistair Milnes, who has served as the company’s Vice President, Human Resources and Communications since January 2021, has assumed the COO role. Mr. Milnes previously led human resources and communications at multinational energy and mineral companies. Both Dr. Skynner and Mr. Milnes are based in the United Kingdom.

 

“We are delighted to announce our recent management team appointments, with Mike Skynner becoming our new CTO and Alistair Milnes moving to the COO role. Mike has been an invaluable contributor to Bicycle’s success to date and has led our platform discovery efforts since joining in early 2016. Following recent promising clinical progress, we believe it is time to focus on accelerating the growth of our proprietary oncology pipeline and on identifying innovative ways to potentially capitalize on our unique technology beyond our current therapeutic focus. I am confident that Mike can help us achieve these objectives.” Dr. Lee added, “I am similarly enthusiastic about Alistair’s appointment as COO and believe his operational experience and track record of successfully identifying, recruiting, and retaining key talent at large, multinational companies will be instrumental in helping guide Bicycle through our next phase of growth.”

 

About Bicycle Therapeutics

 

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICATM targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com.

 

 

 

 

 

Forward Looking Statements

 

This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding the discovery, development and potential commercialization of potential product candidates using Bicycle’s technology; Bicycle’s anticipated advancement of its product candidates, including BT5528, BT8009 and BT7480; the advancement of Bicycle’s product candidate pipeline; anticipated design of, initiation of expansion cohorts in and progression of Bicycle’s clinical trials; the availability of data from clinical trials; the therapeutic potential for Bicycles in oncology and other applications; and Bicycle’s ability to accelerate its product pipeline and identify potentially innovative applications of its technology beyond oncology. Bicycle may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to clinical trial site initiation, patient enrollment and follow-up, as well as to Bicycle’s abilities to meet other anticipated deadlines and milestones, presented by the ongoing COVID-19 pandemic; uncertainties inherent in the initiation and completion of clinical trials and clinical development of Bicycle’s product candidates; the risk that Bicycle may not realize the intended benefits of its technology; availability and timing of results from clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of Bicycle’s product candidates; the risk that Bicycle may not be able to identify additional product candidates or additional applications of its technology; and other important factors, any of which could cause Bicycle’s actual results to differ from those contained in the forward-looking statements, are described in greater detail in the section entitled “Risk Factors” in Bicycle’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 4, 2021, as well as in other filings Bicycle may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Bicycle expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

 

Investors:

David Borah, CFA

VP, Capital Markets & Investor Relations

david.borah@bicycletx.com
617-203-8300

 

Media:

Consilium Strategic Communications

Sukaina Virji or Mary-Jane Elliott

bicycle@consilium-comms.com

  

 

 

 

 

 

 EX-101.SCH 3 bcyc-20220103.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 bcyc-20220103_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 bcyc-20220103_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Common Stock [Member] American Depositary Shares [Member] Statement [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] American Depositary Shares EX-101.PRE 6 bcyc-20220103_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 tm221573d1_ex99-1img001.jpg GRAPHIC begin 644 tm221573d1_ex99-1img001.jpg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htm IDEA: XBRL DOCUMENT v3.21.4
Cover
Jan. 03, 2022
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 03, 2022
Entity File Number 001-38916
Entity Registrant Name Bicycle Therapeutics plc
Entity Central Index Key 0001761612
Entity Tax Identification Number 00-0000000
Entity Incorporation, State or Country Code X0
Entity Address, Address Line One B900
Entity Address, Address Line Two Babraham Research Campus
Entity Address, City or Town Cambridge
Entity Address, Country GB
Entity Address, Postal Zip Code CB22 3AT
City Area Code +44
Local Phone Number 1223 261503
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member]  
Document Information [Line Items]  
Title of 12(b) Security Ordinary shares, nominal value £0.01 per share
No Trading Symbol Flag true
Security Exchange Name NASDAQ
American Depositary Shares [Member]  
Document Information [Line Items]  
Title of 12(b) Security American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share
Trading Symbol BCYC
Security Exchange Name NASDAQ
XML 9 tm221573d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001761612 2022-01-03 2022-01-03 0001761612 us-gaap:CommonStockMember 2022-01-03 2022-01-03 0001761612 bcyc:AmericanDepositarySharesMember 2022-01-03 2022-01-03 iso4217:USD shares iso4217:USD shares 0001761612 false 00-0000000 true 8-K 2022-01-03 Bicycle Therapeutics plc X0 001-38916 B900 Babraham Research Campus Cambridge CB22 3AT GB +44 1223 261503 false false false false Ordinary shares, nominal value £0.01 per share NASDAQ American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share BCYC NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 3 118 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://bicycletherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm221573d1_8k.htm bcyc-20220103.xsd bcyc-20220103_def.xml bcyc-20220103_lab.xml bcyc-20220103_pre.xml tm221573d1_ex99-1.htm http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm221573d1_8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "bcyc-20220103_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm221573d1_8k.htm" ] }, "labelLink": { "local": [ "bcyc-20220103_lab.xml" ] }, "presentationLink": { "local": [ "bcyc-20220103_pre.xml" ] }, "schema": { "local": [ "bcyc-20220103.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 65, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 1, "memberStandard": 1, "nsprefix": "bcyc", "nsuri": "http://bicycletherapeutics.com/20220103", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm221573d1_8k.htm", "contextRef": "From2022-01-03to2022-01-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://bicycletherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm221573d1_8k.htm", "contextRef": "From2022-01-03to2022-01-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "bcyc_AmericanDepositarySharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "American Depositary Shares", "label": "American Depositary Shares [Member]" } } }, "localname": "AmericanDepositarySharesMember", "nsuri": "http://bicycletherapeutics.com/20220103", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 16 0001104659-22-001252-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-001252-xbrl.zip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end